VEGFA and neoplasm: Our studies in preclinical animal models of TNBC suggest that ERO1 genetic inhibition improves the efficacy of a VEGF monoclonal antibody (B20) in restraining the tumor and metastasis as well as the cytotoxic effect of the protein translational activator ISRIB [45,56,58].